礼来公司周三预计2026年利润将超华尔街预期，该全球市值最高药企押注旗下肥胖症药物需求激增，同 时公司筹备于今年晚些时候推出口服减肥药。 责任编辑：李肇孚 礼来公司周三预计2026年利润将超华尔街预期，该全球市值最高药企押注旗下肥胖症药物需求激增，同 时公司筹备于今年晚些时候推出口服减肥药。 公司股价在盘前交易中上涨近7%。 公司股价在盘前交易中上涨近7%。 得益于爆款减肥药泽布替尼的热销，以及正转向自费模式和远程医疗渠道、规模快速扩张的肥胖症市 场，礼来去年成为首家市值突破1万亿美元的制药企业。 礼来的乐观业绩展望，与其竞争对手诺和诺德形成鲜明反差。诺和诺德此前预计今年销售额将大幅下 滑，引发投资者恐慌，且已预警2026年将面临"前所未有的"价格压力。 该药企公告显示，本季度摊薄后每股收益为7.54美元。伦敦证券交易所集团汇编数据显示，分析师此前 预期值为6.67美元。 礼来预计，今年调整后每股收益将达33.50至35美元，高于分析师平均预期的33.23美元。 礼来的乐观业绩展望，与其竞争对手诺和诺德形成鲜明反差。诺和诺德此前预计今年销售额将大幅下 滑，引发投资者恐慌，且已预警2026年将面临"前所未有的" ...

Core Viewpoint - European stock markets continued their strong start to the year, driven by the performance of large companies in sectors such as mining and defense [1] Group 1: Market Performance - The UK FTSE 100 index rose by 1.18%, closing at 10,122.73 points, remaining above the 10,000 mark [1] - The French CAC 40 index increased by 0.32% [1] - The German DAX index saw a slight rise of 0.09% [1] Group 2: Sector Highlights - The defense sector maintained its upward trend, with Swedish fighter jet manufacturer Saab's stock price increasing by 6.6% [1] - Danish company Novo Nordisk's stock price rose nearly 5% following the launch of an oral weight-loss drug in the US, priced significantly lower than similar injectable medications [1]

Market Overview - US stock indices opened higher on January 6, with the Dow Jones Industrial Average at 49,120.33, up 0.29%, the Nasdaq at 23,509.02, up 0.48%, and the S&P 500 at 6,930.89, up 0.42% [2] Precious Metals - Precious metals experienced significant gains, with spot silver surpassing $80 per ounce, increasing nearly 5%, and spot gold rising to over $4,480 per ounce [1] - Other precious metals also saw substantial increases, with palladium and platinum both rising over 6% [1] Semiconductor Sector - Chip stocks saw broad gains, with Microchip Technology rising over 7% and NXP Semiconductors and TSMC both increasing by more than 2% [1] - Microchip Technology raised its net sales forecast for Q3 of fiscal 2026 due to strong demand and market recovery [3] Pharmaceutical Sector - Novo Nordisk shares rose nearly 5% following the launch of its oral weight loss medication in the US, priced significantly lower than injectable alternatives [3] - The monthly cash price for the medication ranges from $149 to $199, with insurance-covered patients paying as little as $25 [3] Data Center Cooling Stocks - Data center cooling stocks experienced a collective decline, with Johnson Controls and Trane Technologies dropping by 10% and Modine by 20% [4] - This decline followed comments from Jensen Huang at CES regarding new server cooling technologies that do not require water cooling [4] Chinese Stocks - The Nasdaq Golden Dragon China Index rose by 0.56%, with many popular Chinese stocks also experiencing gains [4] - Hesai Technology surged over 7% after being selected by NVIDIA as a lidar partner for the "NVIDIA DRIVE AGX Hyperion 10" platform [5] - NIO announced the production of its one millionth vehicle, marking a significant milestone in its growth strategy [5]

Core Insights - Nimbus Therapeutics has signed a multi-year research and licensing agreement with Eli Lilly to develop AI-driven oral therapies for obesity and other metabolic diseases [1][3] - The agreement includes an upfront payment of $55 million from Eli Lilly to Nimbus, with potential milestone payments up to $1.3 billion if the drug is successfully developed and approved [1][3] - The trend of integrating AI in drug discovery aligns with the FDA's recent push to reduce animal testing [1][3] Company Developments - Nimbus previously licensed an AI-designed compound to Takeda Pharmaceutical in 2022, with a total deal value of up to $6 billion, which is currently undergoing late-stage clinical trials [1][3] - This collaboration marks the second partnership between Nimbus and Eli Lilly, following their previous agreement to develop an oral drug for cardiac metabolic diseases [4][5] - Nimbus, based in Boston, focuses on oral drug development across various fields, including cancer, inflammatory diseases, and metabolic diseases [4][5] Industry Trends - Global pharmaceutical companies are competing to develop oral weight-loss medications as alternatives to injectable drugs like Novo Nordisk's semaglutide (Wegovy) and Eli Lilly's tirzepatide (Zepbound) [2][4] - The weight-loss drug market is projected to exceed $150 billion in annual revenue by the early 2030s [2][4] - The collaboration aims to leverage Nimbus's AI technology for drug candidate selection while Eli Lilly contributes its expertise in metabolic diseases [2][4]

Group 1: Global Economic Trends - In 2026, global defense spending is expected to reach a historic high of $2.9 trillion, influenced by geopolitical tensions and U.S. policies, with NATO countries planning to increase defense spending to 5% of GDP by 2035 [3][4] - Global energy demand is projected to grow by only 1% in 2026, driven by economic slowdown and improved energy efficiency, while carbon emissions are expected to increase by just 0.7% [4] - The global financial sector will face a new landscape of policy divergence, with major economies expected to lower interest rates, leading to a nearly 5% growth in global bank loans [7][8] Group 2: Automotive Industry - The global automotive market is anticipated to show a complex picture in 2026, with overall new car sales expected to grow by 2.5%, driven by a 15% increase in electric vehicle sales to 24 million units, with China accounting for over half of this market [3] - U.S. automakers are adjusting their electric vehicle strategies due to reduced policy support, with companies like Audi and Aston Martin delaying electric vehicle launches [3] Group 3: Energy Sector - Non-hydro renewable energy generation is expected to surpass 30% of the global energy mix for the first time, exceeding coal [4] - China is projected to add over 300 GW of wind and solar capacity, sufficient to power millions of households [4] Group 4: Healthcare Industry - Global healthcare spending is expected to grow by 5% to nearly $12 trillion, but actual government investment may remain tight due to prioritization of defense and debt reduction [10] - The pharmaceutical market is expected to see a 5% increase in sales, driven by the popularity of oral weight-loss drugs and the introduction of generic drugs in India and China [10] Group 5: Infrastructure Investment - Global infrastructure investment is projected to grow by 6%, exceeding $30 trillion, with nearly half of the investment concentrated in Asia [10][11] - The U.S. is focusing on digital infrastructure, with major tech companies expected to invest $400 billion in data centers [11] Group 6: Consumer Goods and Retail - Global retail sales growth is expected to be limited to 2% in 2026, with markets like India and the Philippines projected to grow by 5% and 7% respectively [15] - Companies are reshaping supply chains in response to trade tensions, with Nike planning to reduce reliance on Chinese manufacturing [16] Group 7: Tourism and Travel - The global tourism industry is expected to see a strong recovery, with international travelers projected to exceed 2 billion and total spending reaching $1.8 trillion [19][20] - The cruise market is set to expand, with at least 16 new cruise ships expected to enter service despite environmental regulations [20] Group 8: Technology and AI - The use of generative AI in businesses is expected to rise significantly, with the proportion of companies utilizing this technology projected to jump from under 5% in 2023 to about 80% by 2026 [18][19] - The demand for AI-related talent is expected to surge, with India alone needing 1 million skilled professionals by 2026 [19]

Market Overview - U.S. private credit market risks are emerging, with significant exposure concentrated in large banks and insurance funds rather than smaller banks[6] - The U.S. economy grew at its fastest pace in two years in Q3 2025, with GDP growth reaching 4.3%, exceeding expectations of 3.3%[31] Stock Market Performance - A-shares experienced a slight increase, with the Shanghai Composite Index closing at 3,919 points, up 0.07%[15] - U.S. stock indices reached new highs, with the S&P 500 up 0.5% to 6,909.8 points and the Nasdaq up 0.6% to 23,561.8 points[9] Commodity and Currency Trends - Gold and silver prices reached record highs due to U.S. interest rate cut expectations and geopolitical risks[28] - The U.S. dollar index fell to its lowest level since early October, while the Chinese yuan approached the 7 yuan mark against the dollar[28] Fixed Income Market - U.S. Treasury yields rose sharply in the short term following strong GDP data, with the 2-year yield at 3.53%[31] - A $44 billion auction of 7-year Treasury bonds is scheduled, reflecting ongoing market adjustments[31] Sector Insights - The healthcare sector in Latin America showed strong performance, with the medical care sector rising by 2.48%[9] - The real estate sector in China is under focus, with government efforts to stabilize the market and support reasonable financing needs for real estate companies[31]

Market - US stock market closed higher on December 19, with the S&P 500 ending a four-day losing streak, driven by strong earnings from Micron Technology and lower-than-expected CPI data for November, which rose 2.7% year-on-year [1] - Micron Technology's stock surged 10.2% after reporting better-than-expected revenue and profit, indicating strong demand for storage chips, with the high bandwidth storage chip market projected to reach $100 billion [2] - The Philadelphia Fed manufacturing index showed poor performance, while initial jobless claims decreased, and real average weekly earnings rose 0.8% year-on-year in November [1] Company - Micron Technology reported strong demand for storage chips, with its first-quarter revenue and profit exceeding expectations, leading to a stock price increase of over 10% [15] - CarMax's second-hand car sales declined, with same-store sales down 9% year-on-year, as the company anticipates further reductions in gross margins to boost sales [12] - GE Vernova's stock rose 4.3% after Jefferies upgraded its rating to "Buy," citing optimism about its power business and electrification prospects [26] - The Federal Trade Commission (FTC) is investigating Instacart's AI-based pricing tool, which has led to a slight decline in its stock price [22] - ChatGPT mobile app user spending surpassed $3 billion since its launch in May 2023, with projections indicating a significant increase in spending in the coming years [23]

1. Report Industry Investment Rating - No relevant information provided 2. Core Viewpoints of the Report - The global economy is entering the top - region due to the continuous wrong policies in the United States [2] - AI - driven capital expenditure of nearly $3 trillion is expected to drive the market up, but there are risks if it fails to turn into productivity [1] - The shift of foreign capital from the South Korean stock market to Chinese technology sectors is significant [1][2] 3. Summary by Related Catalogs 3.1 Global Economic News - Google's AI infrastructure head says the company must double AI computing power every 6 months and achieve an additional 1000 - fold increase in 4 - 5 years to meet AI service demand [1][2] - US data center planned capacity has soared to 245 gigawatts, with a 45 - gigawatt increase in Q3, and developers are building their own power plants in energy - producing areas [1][2] - Morgan Stanley predicts that the S&P 500 index will reach 7,800 in 2026 driven by AI - related capital expenditure [1] - Foreign capital is leaving the South Korean stock market and flowing into Chinese technology sectors [1][2] - NVIDIA CEO Huang Renxun believes China will win the AI competition due to favorable regulations and low energy costs [2] - High - end chip depreciation concerns are affecting the US stock AI sector [1] - A "sell - Japan" trade is happening, with a rare "triple - kill" in stocks, bonds, and exchange rates [1] - Eli Lilly becomes the first trillion - dollar pharmaceutical company due to strong demand for drugs and sector rotation [1] - In September, over 1.9 million unemployed people in the US aged 25+ with a bachelor's degree accounted for a quarter of the total unemployed [1][2] - Amazon laid off about 4,700 employees, with nearly 40% in engineering, and cut jobs in the game and advertising sectors [1][2] 3.2 Global Economic Logic - The probability of the Fed cutting interest rates in December has risen to 75% after the New York Fed President's dovish remarks [2] - The capital expenditure forecast of the five major tech giants in 2026 has soared to $533 billion, and AI data center construction may need at least $5 trillion in the next five years [2] - US stock retailization is accelerating, and retail investors are major net buyers, especially in the options market [2] - US household excess savings accumulated during the pandemic are almost exhausted, and consumer slowdown has spread to middle - income groups [2] - Economists are worried that large - scale layoffs by well - known companies may be an economic warning signal [2]

Group 1 - The U.S. stock market is experiencing a significant rally, with major indices like the Dow Jones, Nasdaq, S&P 500, and Russell 2000 reaching all-time highs, driven by a favorable interest rate environment [1][4] - The Federal Reserve's recent interest rate cut of 25 basis points is expected to be followed by two more cuts this year, indicating a proactive approach to managing economic risks [2] - The U.K. central bank's decision to slow down quantitative tightening and reduce bond sales is contributing to a global increase in liquidity, further supporting market growth [3] Group 2 - Recent economic data shows a significant drop in initial jobless claims, indicating a stable job market and increasing corporate profit expectations [5] - Key sectors to watch include semiconductors, pharmaceuticals, and AI applications, with companies like Nvidia, Intel, and Novo Nordisk poised for growth due to strong demand and innovative breakthroughs [6] - The current market environment suggests a focus on growth stocks, particularly small-cap stocks and semiconductor companies, while caution is advised against speculative investments lacking solid performance [7] Group 3 - The ongoing interest rate cuts are part of a broader trend of asset revaluation, with historical data indicating that U.S. stocks typically see an average increase of over 15% during such periods [8]

Market Overview - The U.S. stock market showed mixed results on August 19, with the Dow Jones up by 0.64%, while the S&P 500 and Nasdaq fell by 0.01% and 0.66% respectively [1] Federal Reserve and Economic Outlook - Investors are awaiting Federal Reserve Chairman Jerome Powell's speech at the upcoming global central bank conference, focusing on the theme of "Labor Market Transformation: Demographics, Productivity, and Macroeconomic Policy" [3] - Powell faces a challenging economic situation with signs of a cooling labor market and rising inflation due to tariff policies, complicating interest rate decisions [3] - There is an 83% probability that the Federal Reserve will cut rates by 25 basis points in September, according to the FedWatch tool [3] Intel's Stock Surge - Intel's stock surged by nearly 12% after receiving significant investments from the Trump administration and SoftBank Group, with the stock still up over 8% at the time of reporting [4] - The Trump administration is expected to acquire approximately 10% of Intel's shares, potentially providing around $10 billion to support Intel's revival strategy [4] - SoftBank Group plans to invest $2 billion in Intel, aiming to leverage Intel's chip manufacturing technology for artificial intelligence applications [4] Viking Therapeutics' Stock Plunge - Viking Therapeutics' stock plummeted over 41% due to disappointing mid-stage trial data for its experimental oral weight loss drug [5] - The drug VK2735 showed a maximum weight loss of 12.2%, but 28% of participants dropped out of the trial within three months, undermining confidence in its competitiveness against products from Eli Lilly and Novo Nordisk [6] - Other pharmaceutical companies have also faced stock declines due to underwhelming results from weight loss drug trials, highlighting the significant scientific challenges in this emerging field [6]